Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacol Ther
Autores principales: Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2015
Materias:
CPIC Guideline
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4481158/
https://ncbi.nlm.nih.gov/pubmed/25801146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares